Biomarkers for neurodegenerative diseases

[1]  Houeto Jean-Luc.  [Parkinson's disease]. , 2022, La Revue du praticien.

[2]  W. Jagust,et al.  Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease , 2021, JAMA neurology.

[3]  K. Blennow,et al.  Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tau , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[4]  P. Svenningsson,et al.  A multicentre validation study of the diagnostic value of plasma neurofilament light , 2021, Nature Communications.

[5]  Sterling C. Johnson,et al.  Four distinct trajectories of tau deposition identified in Alzheimer’s disease , 2021, Nature Medicine.

[6]  Christopher J. Weber,et al.  The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau , 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[7]  Julia W. McDonald,et al.  Comparison of [11C]UCB-J and [18F]FDG PET in Alzheimer’s disease: A tracer kinetic modeling study , 2021, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[8]  M. Mintun,et al.  Donanemab in Early Alzheimer's Disease. , 2021, The New England journal of medicine.

[9]  W. M. van der Flier,et al.  Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. , 2021, The Lancet. Healthy longevity.

[10]  R. Bateman,et al.  Soluble P‐tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau , 2021, EMBO molecular medicine.

[11]  O. Hansson,et al.  Plasma biomarkers of Alzheimer's disease predict cognitive decline and could improve clinical trials in the cognitively unimpaired elderly , 2021, medRxiv.

[12]  Justin S. Sanchez,et al.  The cortical origin and initial spread of medial temporal tauopathy in Alzheimer’s disease assessed with positron emission tomography , 2021, Science Translational Medicine.

[13]  K. Blennow,et al.  Prediction of future Alzheimer’s disease dementia using plasma phospho-tau combined with other accessible measures , 2021, Nature Medicine.

[14]  R. Bateman,et al.  CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer's disease. , 2020, Brain : a journal of neurology.

[15]  K. Blennow,et al.  Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment , 2020, Alzheimer's Research & Therapy.

[16]  M. Pontecorvo,et al.  The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects , 2020, Brain : a journal of neurology.

[17]  K. Blennow,et al.  Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations , 2020, Nature Aging.

[18]  Christoph N Schlaffner,et al.  Tau PTM Profiles Identify Patient Heterogeneity and Stages of Alzheimer’s Disease , 2020, Cell.

[19]  O. Hansson,et al.  Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease , 2020, JAMA neurology.

[20]  W. Jagust,et al.  18F-flortaucipir PET to autopsy comparisons in Alzheimer's disease and other neurodegenerative diseases. , 2020, Brain : a journal of neurology.

[21]  C. Jack,et al.  Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias , 2020, The Lancet Neurology.

[22]  D. Walsh,et al.  Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease , 2020, Brain : a journal of neurology.

[23]  B. de Strooper,et al.  Translating genetic risk of Alzheimer’s disease into mechanistic insight and drug targets , 2020, Science.

[24]  W. M. van der Flier,et al.  Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology , 2020, Alzheimer's Research & Therapy.

[25]  Xiongwei Zhu,et al.  Skin α-Synuclein Aggregation Seeding Activity as a Novel Biomarker for Parkinson Disease , 2020, JAMA neurology.

[26]  K. Blennow,et al.  Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias , 2020, Neurology.

[27]  C. Adler,et al.  Blinded RT‐QuIC Analysis of α‐Synuclein Biomarker in Skin Tissue From Parkinson's Disease Patients , 2020, Movement disorders : official journal of the Movement Disorder Society.

[28]  J. Jansen,et al.  A Comprehensive View on MRI Techniques for Imaging Blood-Brain Barrier Integrity. , 2020, Investigative radiology.

[29]  B. Bloem,et al.  Towards early disease modification of Parkinson’s disease: a review of lessons learned in the Alzheimer field , 2020, Journal of Neurology.

[30]  Philip S. Insel,et al.  Comparing progression biomarkers in clinical trials of early Alzheimer’s disease , 2020, Annals of clinical and translational neurology.

[31]  K. Blennow,et al.  Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. , 2020, JAMA.

[32]  K. Blennow,et al.  Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline , 2020, Acta Neuropathologica.

[33]  Mark E. Schmidt,et al.  Multitracer model for staging cortical amyloid deposition using PET imaging , 2020, Neurology.

[34]  Muhammad Naveed Iqbal Qureshi,et al.  18F-MK-6240 PET for early and late detection of neurofibrillary tangles. , 2020, Brain : a journal of neurology.

[35]  M. Goedert,et al.  Cryo-EM structures of tau filaments. , 2020, Current opinion in structural biology.

[36]  David T. Jones,et al.  Predicting future rates of tau accumulation on PET , 2020, Brain : a journal of neurology.

[37]  B. Boeve,et al.  Alpha-Synuclein Oligomers and Neurofilament Light Chain in Spinal Fluid Differentiate Multiple System Atrophy from Lewy Body Synucleinopathies. , 2020, Annals of neurology.

[38]  M. Mintun,et al.  Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer’s disease pathology: a clinicopathological study , 2020, EJNMMI Research.

[39]  Ryan S. O'Dell,et al.  In vivo measurement of widespread synaptic loss in Alzheimer's disease with SV2A PET , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[40]  O. Hansson,et al.  Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders , 2020, JAMA neurology.

[41]  K. Blennow,et al.  Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts , 2020, The Lancet Neurology.

[42]  G. Plazzi,et al.  Ultrasensitive RT-QuIC assay with high sensitivity and specificity for Lewy body-associated synucleinopathies , 2020, Acta Neuropathologica.

[43]  Val J Lowe,et al.  Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. , 2020, JAMA neurology.

[44]  Philip S. Insel,et al.  Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer’s disease , 2020, Science Advances.

[45]  J. Trojanowski,et al.  Protein transmission in neurodegenerative disease , 2020, Nature Reviews Neurology.

[46]  K. Blennow,et al.  Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia , 2020, Nature Medicine.

[47]  Nick C Fox,et al.  A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease , 2020, Nature Medicine.

[48]  L. Kappos,et al.  Blood neurofilament light levels segregate treatment effects in multiple sclerosis , 2020, Neurology.

[49]  K. Nilsson,et al.  Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy , 2020, Nature.

[50]  Alzheimer's Disease Neuroimaging Initiative.  Functional brain architecture is associated with the rate of tau accumulation in Alzheimer’s disease , 2020 .

[51]  Yiyun Huang,et al.  Synaptic Changes in Parkinson Disease Assessed with in vivo Imaging , 2020, Annals of neurology.

[52]  D. Airey,et al.  Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease , 2020 .

[53]  G. Frisoni,et al.  Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.

[54]  K. Blennow,et al.  Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration , 2020, Nature Medicine.

[55]  A. Fagan,et al.  Concordance of Lumipulse cerebrospinal fluid t‐tau/Aβ42 ratio with amyloid PET status , 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[56]  Jesse A. Brown,et al.  Prospective longitudinal atrophy in Alzheimer’s disease correlates with the intensity and topography of baseline tau-PET , 2020, Science Translational Medicine.

[57]  M. Grossman,et al.  Validation of the Movement Disorder Society Criteria for the Diagnosis of 4‐Repeat Tauopathies , 2020, Movement disorders : official journal of the Movement Disorder Society.

[58]  G. Kerchner,et al.  Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology. , 2019, Brain : a journal of neurology.

[59]  J. Trojanowski,et al.  Predicting clinical decline and conversion to Alzheimer’s disease or dementia using novel Elecsys Aβ(1–42), pTau and tTau CSF immunoassays , 2019, Scientific Reports.

[60]  Philip S. Insel,et al.  Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease , 2019, EMBO molecular medicine.

[61]  James G. Bollinger,et al.  High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis , 2019, Neurology.

[62]  Nathalie Van Den Berge,et al.  Brain-First versus Gut-First Parkinson’s Disease: A Hypothesis , 2019, Journal of Parkinson's disease.

[63]  D. Dickson,et al.  The neuropathological diagnosis of Alzheimer’s disease , 2019, Molecular Neurodegeneration.

[64]  O. Hansson,et al.  Staging β-Amyloid Pathology With Amyloid Positron Emission Tomography. , 2019, JAMA neurology.

[65]  K. Blennow,et al.  Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease–Related β-Amyloid Status , 2019, JAMA neurology.

[66]  W. Jagust,et al.  Biomarkers for tau pathology , 2019, Molecular and Cellular Neuroscience.

[67]  Paolo Eusebi,et al.  CSF and blood biomarkers for Parkinson's disease , 2019, The Lancet Neurology.

[68]  K. Blennow,et al.  NFL is a marker of treatment response in children with SMA treated with nusinersen , 2019, Journal of Neurology.

[69]  C. Jack,et al.  Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report , 2019, Brain : a journal of neurology.

[70]  P. Lewczuk,et al.  Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease , 2019, Alzheimer's Research & Therapy.

[71]  Stephen Salloway,et al.  A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer’s disease dementia , 2019, Brain : a journal of neurology.

[72]  M. Carrillo,et al.  Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia , 2019, JAMA.

[73]  Claudio Soto,et al.  Comparative study of cerebrospinal fluid α‐synuclein seeding aggregation assays for diagnosis of Parkinson's disease , 2019, Movement disorders : official journal of the Movement Disorder Society.

[74]  Elisabet Englund,et al.  Correlation of In Vivo [18F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology , 2019, JAMA neurology.

[75]  Alan C. Evans,et al.  Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease , 2019, bioRxiv.

[76]  Nick C Fox,et al.  Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease , 2019, Nature Medicine.

[77]  Keith A. Johnson,et al.  The impact of amyloid‐beta and tau on prospective cognitive decline in older individuals , 2018, Annals of neurology.

[78]  A. Fagan,et al.  Blood-brain barrier breakdown is an early biomarker of human cognitive dysfunction , 2018, Nature Medicine.

[79]  K. Blennow,et al.  Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer’s disease , 2018, Alzheimer's & Dementia.

[80]  B. Miller,et al.  Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders , 2018, JAMA.

[81]  W. M. van der Flier,et al.  Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes , 2018, Annals of neurology.

[82]  Ranjan Duara,et al.  Use of Flutemetamol F 18–Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment , 2018, JAMA neurology.

[83]  Ludwig Kappos,et al.  Neurofilaments as biomarkers in neurological disorders , 2018, Nature Reviews Neurology.

[84]  K. Blennow,et al.  Biomarkers for Alzheimer's disease: current status and prospects for the future , 2018, Journal of internal medicine.

[85]  S. Linse,et al.  Secondary nucleation in amyloid formation. , 2018, Chemical communications.

[86]  C. Murray,et al.  On the road to universal health care in Indonesia, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2018, The Lancet.

[87]  Philip S. Insel,et al.  Associations between tau, Aβ, and cortical thickness with cognition in Alzheimer disease , 2019, Neurology.

[88]  Elizabeth Mormino,et al.  Combined neuropathological pathways account for age‐related risk of dementia , 2018, Annals of neurology.

[89]  R. Bateman,et al.  Erratum: Tau Kinetics in Neurons and the Human Central Nervous System (Neuron (2018) 97(6) (1284–1298.e7)(S0896627318301363)(10.1016/j.neuron.2018.02.015)) , 2018 .

[90]  J. Trojanowski,et al.  Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology , 2018, Acta Neuropathologica.

[91]  Brian A. Gordon,et al.  Tau Kinetics in Neurons and the Human Central Nervous System , 2018, Neuron.

[92]  Christopher G Schwarz,et al.  Longitudinal tau PET in ageing and Alzheimer’s disease , 2018, Brain : a journal of neurology.

[93]  J. Trojanowski,et al.  CSF biomarkers of Alzheimer’s disease concord with amyloid-β PETand predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts , 2018, Alzheimer's & Dementia.

[94]  Yue Huang,et al.  Reader response: Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium , 2018, Neurology.

[95]  Keith A. Johnson,et al.  Structural tract alterations predict downstream tau accumulation in amyloid-positive older individuals , 2018, Nature Neuroscience.

[96]  Andrew J. Saykin,et al.  Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer disease: a longitudinal study , 2018, The Lancet Neurology.

[97]  C. Rowe,et al.  High performance plasma amyloid-β biomarkers for Alzheimer’s disease , 2018, Nature.

[98]  Jorge Sepulcre,et al.  Structural tract alterations predict down-stream tau accumulation in amyloid positive older individuals , 2018, Nature Neuroscience.

[99]  Daniel R. Schonhaut,et al.  Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease , 2017, Brain : a journal of neurology.

[100]  Theresa M. Harrison,et al.  Entorhinal Tau Pathology, Episodic Memory Decline, and Neurodegeneration in Aging , 2017, The Journal of Neuroscience.

[101]  A. Al-Chalabi,et al.  Amyotrophic lateral sclerosis , 2017, The Lancet.

[102]  M. Goedert,et al.  Neurodegeneration and the ordered assembly of α-synuclein , 2017, Cell and Tissue Research.

[103]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[104]  W. Jagust,et al.  Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity , 2017, Nature Communications.

[105]  G. Rizzo,et al.  Accuracy of clinical diagnosis of dementia with Lewy bodies: a systematic review and meta-analysis , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.

[106]  James G. Bollinger,et al.  Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis , 2017, Alzheimer's & Dementia.

[107]  Alan J. Thomas,et al.  Diagnosis and management of dementia with Lewy bodies , 2017, Neurology.

[108]  M. Weiner,et al.  Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons , 2017, JAMA.

[109]  Marina Boccardi,et al.  Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework , 2017, Neurobiology of Aging.

[110]  K. Blennow,et al.  CSF Aβ1-42 - an excellent but complicated Alzheimer's biomarker - a route to standardisation. , 2017, Clinica chimica acta; international journal of clinical chemistry.

[111]  K. Blennow,et al.  Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype , 2017, Neurobiology of Aging.

[112]  Clifford R. Jack,et al.  Tau aggregation influences cognition and hippocampal atrophy in the absence of beta-amyloid: a clinico-imaging-pathological study of primary age-related tauopathy (PART) , 2017, Acta Neuropathologica.

[113]  H. Braak,et al.  Potential Pathways of Abnormal Tau and α-Synuclein Dissemination in Sporadic Alzheimer's and Parkinson's Diseases. , 2016, Cold Spring Harbor perspectives in biology.

[114]  Knut Engedal,et al.  Frontotemporal Dementia , 2016, Journal of geriatric psychiatry and neurology.

[115]  M. Esiri,et al.  Alpha‐synuclein RT‐QuIC in the CSF of patients with alpha‐synucleinopathies , 2016, Annals of clinical and translational neurology.

[116]  Hanna Cho,et al.  In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum , 2016, Annals of neurology.

[117]  K. Jellinger,et al.  Accuracy of clinical diagnosis of Parkinson disease: A systematic review and meta-analysis , 2016, Neurology.

[118]  K. Blennow,et al.  CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis , 2016, The Lancet Neurology.

[119]  K. Blennow,et al.  Plasma β-amyloid in Alzheimer’s disease and vascular disease , 2016, Scientific Reports.

[120]  Daniel R. Schonhaut,et al.  Tau PET patterns mirror clinical and neuroanatomical variability in Alzheimer's disease. , 2016, Brain : a journal of neurology.

[121]  O. Hansson,et al.  Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography , 2016, Brain : a journal of neurology.

[122]  Eric Karran,et al.  The Cellular Phase of Alzheimer’s Disease , 2016, Cell.

[123]  G. Rizzo,et al.  Accuracy of clinical diagnosis of Parkinson disease , 2016, Neurology.

[124]  J. Sevigny,et al.  Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials: Experience in a Phase 1b Clinical Trial , 2016, Alzheimer disease and associated disorders.

[125]  Jorge Sepulcre,et al.  Tau positron emission tomographic imaging in aging and early Alzheimer disease , 2016, Annals of neurology.

[126]  M. Weiner,et al.  Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease. , 2015, Brain : a journal of neurology.

[127]  S. Spina,et al.  Frontotemporal dementia , 2015, The Lancet.

[128]  B. Boeve,et al.  Lewy body dementias , 2015, The Lancet.

[129]  M. Prince,et al.  World Alzheimer Report 2015 - The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends , 2015 .

[130]  A. Lang,et al.  Parkinson's disease , 2015, The Lancet.

[131]  H. Birnbaum,et al.  Medical costs of Alzheimer's disease misdiagnosis among US Medicare beneficiaries , 2015, Alzheimer's & Dementia.

[132]  John Seibyl,et al.  Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study , 2015, Alzheimer's & Dementia.

[133]  D. Y. Lee,et al.  Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. , 2015, JAMA.

[134]  Ranjan Duara,et al.  Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density. , 2015, JAMA neurology.

[135]  Janna H. Neltner,et al.  Primary age-related tauopathy (PART): a common pathology associated with human aging , 2014, Acta Neuropathologica.

[136]  Nick C Fox,et al.  Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[137]  C. Rowe,et al.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.

[138]  Keith A. Johnson,et al.  Appropriate Use Criteria for Amyloid PET: A Report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association , 2013, The Journal of Nuclear Medicine.

[139]  Peter Herscovitch,et al.  Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association , 2013, Alzheimer's & Dementia.

[140]  R. Coleman,et al.  Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study , 2012, The Lancet Neurology.

[141]  W. Kukull,et al.  Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 , 2012, Journal of neuropathology and experimental neurology.

[142]  Henrik Zetterberg,et al.  Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. , 2012, Archives of general psychiatry.

[143]  B. Strooper,et al.  The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics , 2011, Nature Reviews Drug Discovery.

[144]  Beppie van den Bogaerde,et al.  Clinical practice , 2011, European Journal of Pediatrics.

[145]  R. Petersen.  Clinical practice. Mild cognitive impairment. , 2011, The New England journal of medicine.

[146]  Chengjie Xiong,et al.  Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease , 2011, Alzheimer's Research & Therapy.

[147]  D. Brooks.  Imaging Approaches to Parkinson Disease , 2010, Journal of Nuclear Medicine.

[148]  Carol Brayne,et al.  Age, neuropathology, and dementia. , 2009, The New England journal of medicine.

[149]  Hardeep Singh,et al.  Missed and Delayed Diagnosis of Dementia in Primary Care: Prevalence and Contributing Factors , 2009, Alzheimer disease and associated disorders.

[150]  R. Bateman,et al.  Measuring target effect of proposed disease-modifying therapies in Alzheimer’s disease , 2008, Neurotherapeutics.

[151]  F. Schmidt.  Meta-Analysis , 2008 .

[152]  Sudha Seshadri,et al.  Lifetime risk of stroke and dementia: current concepts, and estimates from the Framingham Study , 2007, The Lancet Neurology.

[153]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[154]  B. Miller,et al.  CME Practice parameter : Diagnosis of dementia ( an evidence-based review ) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .

[155]  Eka Swadiansa.  The hypothesis , 1990 .

[156]  Reisa A. Sperling,et al.  Alzheimer's disease , 2015, Nature Reviews Disease Primers.

[157]  H. Braak,et al.  100 years of Lewy pathology , 2013, Nature Reviews Neurology.

[158]  Maja O’Connor.  LONGITUDINAL STUDY , 2013 .

[159]  M. A. Sheddi.  A clinicopathological study , 2012 .

[160]  A. Ludolph,et al.  Amyotrophic lateral sclerosis. , 2012, Current opinion in neurology.

[161]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[162]  V. Preedy,et al.  Prospective Cohort Study , 2010 .

[163]  R. Fry,et al.  COVID-19 Infection Risk amongst 14,104 Vaccinated Care Home Residents: A national observational longitudinal cohort study in Wales, United Kingdom, December 2020 to March 2021 , 2021, medRxiv.